Molecular Imaging Service of PARP

The overexpression of poly-(ADP ribose) polymerase (PARP) in various cancers, has propelled the development of PARP inhibitors (PARPis) as a therapeutic strategy. Additionally, imaging techniques that can accurately assess PARP expression levels are essential for predicting patient responses to PARP-targeted therapies. Alfa Cytology offers comprehensive molecular imaging services of PARP for our clients.

Introduction to Molecular Imaging of PARP

Recent advancements in imaging modalities, particularly positron emission tomography (PET) and single photon emission computed tomography (SPECT), have facilitated the non-invasive evaluation of PARP1 expression in tumors. The development of radiolabeled PARPis, such as ¹⁸F-Olaparib and ¹⁸F-PARPi, has shown promising results in clinical trials, demonstrating the potential for imaging agents to guide therapeutic decisions. These imaging techniques contribute to a more personalized approach in cancer treatment.

Fig. 1 Progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. (Wang Q., et al. 2022)

Imaging Tracer Development for PARP

To assess PARP1 levels, several imaging probes with fluorescent or β/γ emitting radionuclides have been proposed, three of which have entered ongoing clinical evaluation.

NCT	Tracer	Structure	Modality of Imaging	Phase
NCT03631017	¹⁸F-PARPi		PET/CT
NCT03604315	¹⁸F-FTT		PET/CT

Our Services

At Alfa Cytology, we offer state-of-the-art imaging services focused on PARP-targeted therapies, leveraging our expertise in molecular imaging to enhance cancer diagnostics and treatment planning. Our offerings are designed to support the entire spectrum of imaging needs in oncology, focusing on accuracy, reliability, and innovation.

Synthesis of High-quality Radiolabeled PARP Inhibitors

We focus on synthesizing high-quality radiolabeled compounds that enhance the visualization of PARP1 expression in tumors. Key isotopes like ¹⁸F and 131^I are utilized, leveraging their favorable properties for PET and SPECT imaging.

Selection of Parent Compounds
Radiolabeling Techniques

Optimization of Chemical Properties

Alfa Cytology employs advanced chemistry techniques to produce tracers with superior binding affinity and specificity for PARP. During the synthesis process, we focus on optimizing several chemical properties of the radiolabeled inhibitors:

Binding Affinity
Stability
Lipophilicity

Preclinical Imaging
Studies

Preclinical imaging studies are designed to evaluate the biodistribution and pharmacokinetics of radiolabeled PARP inhibitors in tumor models.

Selection of Animal Models of PARP-Related Cancers
Evaluating the Biodistribution and Pharmacokinetics
Assessing Tumor Uptake and Specificity

Workflow of Our Imaging Services

Alfa Cytology offers customized imaging solutions tailored to specific needs. Whether it involves developing novel tracers or designing specific preclinical studies, our flexible approach ensures that we meet the diverse demands of our partners in the oncology field. To discuss your specific research needs, please reach out to our expert team at Alfa Cytology.

Reference

Wang Q., Zhang J. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. European Journal of Medicinal Chemistry. 2022, 242: 114690.

For research use only. Not intended for any clinical use.